[go: up one dir, main page]

AR046142A1 - PROCESO PARA FABRICAR ARIPIPRAZOL ESTERIL DE TAMANO DE PARTICULA PROMEDIO MENOR QUE 100 µM PERO MAYOR QUE 25 µM - Google Patents

PROCESO PARA FABRICAR ARIPIPRAZOL ESTERIL DE TAMANO DE PARTICULA PROMEDIO MENOR QUE 100 µM PERO MAYOR QUE 25 µM

Info

Publication number
AR046142A1
AR046142A1 ARP040103850A ARP040103850A AR046142A1 AR 046142 A1 AR046142 A1 AR 046142A1 AR P040103850 A ARP040103850 A AR P040103850A AR P040103850 A ARP040103850 A AR P040103850A AR 046142 A1 AR046142 A1 AR 046142A1
Authority
AR
Argentina
Prior art keywords
aripiprazole
particle size
jet
stream
solution
Prior art date
Application number
ARP040103850A
Other languages
English (en)
Inventor
Margaret Gleeson
Soojin Kim
Donald Kientzler
San Kiang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34549310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR046142(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR046142A1 publication Critical patent/AR046142A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0009—Crystallisation cooling by heat exchange by direct heat exchange with added cooling fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0081—Use of vibrations, e.g. ultrasound
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/06—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un proceso para fabricar aripiprazol estéril que tiene un tamano de partícula promedio menor que 100 micrones pero preferentemente mayor que 25 micrones empleando un procedimiento de cristalización por chorros convergentes. El aripiprazol a granel resultante del tamano de partícula deseado puede ser utilizado para formar una formulación de aripiprazol secada por congelamiento, estéril, la cual durante la constitución con agua y la inyección intramuscular libera aripiprazol durante un período de al menos aproximadamente una semana y hasta aproximadamente ocho semanas. Reivindicación 1: Un proceso para preparar aripiprazol cristalino estéril de tamano de partícula pequeno deseado y de distribución estrecha de tamano de partícula caracterizado porque comprende: (a) proporcionar una corriente de chorro de una solución de aripiprazol en un solvente orgánico; (b) proporcionar una corriente de chorro de anti-solvente, el cual es capaz de iniciar la precipitación del aripiprazol de la solución; (c) provocar que la corriente de chorro de la solución de aripiprazol en el solvente y la corriente de chorro del anti-solvente choquen entre sí y se golpeen una contra la otra para crear una turbulencia elevada en su punto de impacto, cada corriente de chorro tiene una velocidad lineal suficiente para lograr un micromezclado de intensidad elevada de cada corriente previo a la nucleación, para producir una suspensión de cristales de monohidrato de aripiprazol; y (d) recuperar los cristales de monohidrato de aripiprazol de tamano de partícula pequeno deseado y de distribución estrecha de tamano de partícula. Reivindicación 15: Un proceso de preparación de aripiprazol estéril de tamano de partícula pequeno deseado y distribución estrecha de tamano, caracterizado porque comprende: (a) proporcionar una corriente de chorro de una solución de aripiprazol en etanol/agua calentada a una temperatura dentro del intervalo desde aproximadamente 70 hasta aproximadamente 85sC; (b) proporcionar una corriente de chorro de agua desionizada la cual está a una temperatura dentro del intervalo desde aproximadamente 2 hasta aproximadamente 40sC; (c) provocar que la corriente de chorro de la solución de aripiprazol en etanol y la corriente de chorro de agua, cada una a una velocidad de flujo dentro del intervalo desde aproximadamente 0,2 hasta aproximadamente 0,3 Kg/min, en donde son empleadas boquillas de chorro de diámetro interno de 0, 0508 cm (0,02 pulgadas), choquen entre sí para crear una turbulencia elevada en su punto de impacto para lograr un micromezclado de intensidad elevada de cada corriente previo a la nucleación, para formar una suspensión de cristales de monohidrato de aripiprazol; y (d) recuperar los cristales de monohidrato de aripiprazol que tienen un tamano de partícula promedio aproximadamente 95% menor que 100 micrones.
ARP040103850A 2003-10-23 2004-10-22 PROCESO PARA FABRICAR ARIPIPRAZOL ESTERIL DE TAMANO DE PARTICULA PROMEDIO MENOR QUE 100 µM PERO MAYOR QUE 25 µM AR046142A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51388603P 2003-10-23 2003-10-23

Publications (1)

Publication Number Publication Date
AR046142A1 true AR046142A1 (es) 2005-11-23

Family

ID=34549310

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103850A AR046142A1 (es) 2003-10-23 2004-10-22 PROCESO PARA FABRICAR ARIPIPRAZOL ESTERIL DE TAMANO DE PARTICULA PROMEDIO MENOR QUE 100 µM PERO MAYOR QUE 25 µM

Country Status (16)

Country Link
US (3) US20050152981A1 (es)
EP (1) EP1675593B1 (es)
JP (1) JP4875984B2 (es)
KR (1) KR101121345B1 (es)
CN (1) CN1871007A (es)
AR (1) AR046142A1 (es)
AU (1) AU2004284904B2 (es)
BR (1) BRPI0415754A (es)
CA (1) CA2543248C (es)
CO (1) CO5670354A2 (es)
ES (1) ES2632499T3 (es)
IL (1) IL175008A (es)
MX (1) MXPA06004333A (es)
PE (1) PE20050810A1 (es)
TW (1) TWI371274B (es)
WO (1) WO2005041970A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7714129B2 (en) * 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
ATE529409T1 (de) * 2003-12-16 2011-11-15 Teva Pharma Verfahren zur herstellung von kristallinen aripiprazolformen
US20050215791A1 (en) * 2004-02-05 2005-09-29 Ben-Zion Dolitzky Process for preparing aripiprazole
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
CN101111481A (zh) * 2004-11-18 2008-01-23 斯索恩有限公司 制备结晶阿立哌唑的方法
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
EP1919453A2 (en) * 2005-12-22 2008-05-14 Teva Pharmaceutical Industries Ltd Processes for reducing particle size of aripiprazole
US8420122B2 (en) 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
EP2012753A2 (en) * 2006-04-28 2009-01-14 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
WO2008051541A2 (en) * 2006-10-24 2008-05-02 Cambrex Charles City, Inc. Process for preparing anhydrous aripirazole type i
CN101172966B (zh) * 2007-04-06 2012-08-29 重庆医药工业研究院有限责任公司 一种阿立哌唑微晶的制备方法
JP4879349B2 (ja) 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
GB0909154D0 (en) 2008-09-25 2009-07-08 Nanomaterials Tech Pte Ltd A process for making particles for delivery of drug nanoparticles
DE102009008478A1 (de) * 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
CN101507908B (zh) * 2009-04-09 2010-12-01 北京化工大学 微通道套管式装置及其应用
KR101823706B1 (ko) * 2010-03-22 2018-01-30 인스틸로 게엠베하 마이크로입자 또는 나노입자의 제조 방법 및 제조 장치
CN101816913B (zh) * 2010-05-20 2015-10-21 吴传斌 一种微球制造方法及制造设备
NZ603076A (en) 2010-08-24 2014-12-24 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyril derivative and silicone oil and/or silicone oil derivative
WO2012053654A1 (en) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
ES2884825T3 (es) * 2011-01-24 2021-12-13 Otsuka Pharma Co Ltd Dispositivo médico que contiene una composición de torta que comprende aripiprazol como principio activo y composición de torta que comprende aripiprazol como principio activo
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
JP6034377B2 (ja) 2011-06-27 2016-11-30 シャンハイ チョンシ ファーマシューティカル コーポレイション アリピプラゾール医薬製剤及びその調製方法
CN102850268B (zh) 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US9732068B1 (en) * 2013-03-15 2017-08-15 GenSyn Technologies, Inc. System for crystalizing chemical compounds and methodologies for utilizing the same
AR096131A1 (es) 2013-04-30 2015-12-09 Otsuka Pharma Co Ltd Preparado oral sólido que comprende aripiprazol y un método para producir un preparado oral sólido que comprende aripiprazol
MA55917A (fr) * 2014-08-25 2022-03-16 Alkermes Pharma Ireland Ltd Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
CA3026452C (en) * 2015-06-04 2023-03-21 Crititech, Inc. Nozzle assembly and methods for use
US20190160002A1 (en) 2016-07-28 2019-05-30 Mylan Laboratories Limited Process for preparing sterile aripiprazole formulation
CN111346397B (zh) * 2020-03-11 2022-03-29 天津大学 适用于溶析结晶或反应结晶的加料设备

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
ES2078447T3 (es) * 1990-06-15 1995-12-16 Merck & Co Inc Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.
JP3862957B2 (ja) * 1999-01-29 2006-12-27 ブリストル−マイヤーズ スクイブ カンパニー 音波衝突ジェット結晶化装置及び方法
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
YU34501A (sh) * 2000-05-26 2003-10-31 Pfizer Products Inc. Postupak reaktivne kristalizacije radi povećanja veličine čestica
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
BR0309625A (pt) * 2002-04-29 2005-03-08 Bristol Myers Squibb Co Sistema de cristalização que utiliza atomização
MXPA04011064A (es) * 2002-05-10 2005-02-14 Squibb Bristol Myers Co Sistema de cristalizacion que usa homogenizacion.
WO2004083183A1 (en) * 2003-03-21 2004-09-30 Hetero Drugs Limited Novel crystalline forms of aripiprazole
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole

Also Published As

Publication number Publication date
CA2543248A1 (en) 2005-05-12
ES2632499T3 (es) 2017-09-13
TWI371274B (en) 2012-09-01
TW200518783A (en) 2005-06-16
AU2004284904A1 (en) 2005-05-12
IL175008A (en) 2014-11-30
JP4875984B2 (ja) 2012-02-15
PE20050810A1 (es) 2005-09-25
EP1675593A4 (en) 2007-04-25
JP2007509153A (ja) 2007-04-12
CN1871007A (zh) 2006-11-29
KR101121345B1 (ko) 2012-03-09
CA2543248C (en) 2013-04-02
US20110166352A1 (en) 2011-07-07
EP1675593A1 (en) 2006-07-05
WO2005041970A1 (en) 2005-05-12
US20130161848A1 (en) 2013-06-27
EP1675593B1 (en) 2017-05-31
US20050152981A1 (en) 2005-07-14
BRPI0415754A (pt) 2006-12-19
KR20070090070A (ko) 2007-09-05
US9066848B2 (en) 2015-06-30
IL175008A0 (en) 2006-08-20
AU2004284904B2 (en) 2010-05-20
CO5670354A2 (es) 2006-08-31
MXPA06004333A (es) 2006-06-05

Similar Documents

Publication Publication Date Title
AR046142A1 (es) PROCESO PARA FABRICAR ARIPIPRAZOL ESTERIL DE TAMANO DE PARTICULA PROMEDIO MENOR QUE 100 µM PERO MAYOR QUE 25 µM
Nayak et al. Spontaneous formation of nanospiked microstructures in germanium by femtosecond laserirradiation
ES2175420T3 (es) Particulas ligeras aerodinamicas para la difusion de medicamentos en el aparato respiratorio.
JP2012504431A5 (es)
EP1883447A4 (en) HIGH-SPEED LIQUID GAS STREAM DEVICE FOR THE ADMINISTRATION OF THERAPEUTIC SUBSTANCES
ES2358319T3 (es) Sistema de liberación de fármaco del tipo polímero biodegradable.
TW201237950A (en) Substrate treatment apparatus
PT1343368E (pt) Dispositivo e utilização em ligação com medidas fitossanitárias.
US20180261715A1 (en) Sapphire collector for reducing mechanical damage during die level laser lift-off
AR043579A1 (es) Procedimiento para la preparacion de ciclesonida cristalina con un tamano definido de particulas
CN103199413B (zh) 端泵激光器的冷却方法和冷却装置
CN103316442B (zh) 一种微水雾幕喷头
CN103590921B (zh) 可调式凝胶推进剂三射流撞击雾化装置
JP2006000753A (ja) 洗浄材製造方法、洗浄材製造装置及び洗浄システム
Huang et al. Inherent-opening-controlled pattern formation in carbon nanotube arrays
ES2183522T3 (es) Cristalizacion de lactitol, producto de lactitol cristalino y utilizacion del mismo.
KR102779039B1 (ko) 노덮개 세정장치, 노덮개의 세정방법
CN204017453U (zh) 一种新型海带冷却池的除泡沫结构
RU2014143027A (ru) Устройство для доставки офтальмических лекарственных средств и способы применения
CN109174482A (zh) 一种异步旋转的高均匀度微喷头
CZ304511B6 (cs) Způsob výroby technického sněhu a zařízení k provádění tohoto způsobu
TWI377987B (es)
CN210233956U (zh) 一种用于pe管的增强型冷却装置
CN107585769B (zh) 一种制备颗粒硅籽晶的系统及方法
RU2001122613A (ru) Способ обработки некротической ткани

Legal Events

Date Code Title Description
FB Suspension of granting procedure